1P-LSD is a research chemical and LSD analogue that first appeared in 2015. It acts as a prodrug for LSD, being rapidly metabolized into LSD in the body, with effects reported as virtually indistinguishable from LSD itself. Typically sold on blotter paper.
Perspectives
“It is hypothesized that 1P-LSD is a prodrug to LSD, meaning that they would be functionally indistinguishable in vivo. An enjoyable and valuable substance with subtle but distinguishable differences from LSD.”
“I have experienced so many beautiful moments, and I believe learned much, through the use of this remarkable drug. Mild aftereffects are well worth enduring, given the perceived positives and benefits.”
Rapid withinβsession tachyphylaxis; reβdosing the same day yields little additional effect. Substantial decay by ~7 days; nearβbaseline at ~14 days for most, though individual variability exists.